Guard Therapeutics International (OM:GUARD) - Aandelenkoers, Nieuws & Analyse

GUARD Overzicht aandelen

Guard Therapeutics International AB (publ), een farmaceutisch bedrijf, identificeert, ontwikkelt en commercialiseert therapieën voor de diagnose en behandeling van acute nierschade in Zweden.

Over het bedrijf

GUARD fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( SEK0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 13.5% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( SEK302M )

+ 1 meer risico

Guard Therapeutics International AB (publ) Concurrenten

Medivir

OM:MVIR

SEK 324.2m

Lipum

OM:LIPUM

SEK 311.8m

Alzinova

OM:ALZ

SEK 324.6m

Curasight

NGM:CURAS

DKK 236.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Guard Therapeutics International
Historische aandelenkoersen
Huidige aandelenkoers	SEK 24.60
52 Week Hoogtepunt	SEK 46.00
52 Week Laag	SEK 16.00
Bèta	-0.077
11 maand verandering	-8.89%
3 maanden verandering	-11.51%
1 Jaar Verandering	-23.36%
33 jaar verandering	-63.82%
5 jaar verandering	-60.95%
Verandering sinds IPO	-99.73%

Recent nieuws en updates

Recent updates

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Apr 18

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Jan 04

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

Sep 20

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

Apr 06

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Sep 09

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Feb 19

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Aug 17

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Apr 19

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Jan 04

Rendement voor aandeelhouders

	GUARD	SE Biotechs	SE Markt
7D	1.7%	-2.3%	-1.9%
1Y	-23.4%	32.0%	21.8%

Rendement versus industrie: GUARD presteerde slechter dan de Swedish Biotechs -sector, die het afgelopen jaar een rendement van 32 % opleverde.

Rendement versus markt: GUARD presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 21.8 % opleverde.

Prijsvolatiliteit

Is GUARD's price volatile compared to industry and market?
GUARD volatility
GUARD Average Weekly Movement	6.9%
Biotechs Industry Average Movement	8.7%
Market Average Movement	5.4%
10% most volatile stocks in SE Market	10.9%
10% least volatile stocks in SE Market	3.2%

Stabiele aandelenkoers: GUARD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van GUARD is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	11	Tobias Agervald	guardtherapeutics.com

Guard Therapeutics International AB (publ), een farmaceutisch bedrijf, identificeert, ontwikkelt en commercialiseert therapieën voor de diagnose en behandeling van acute nierschade in Zweden. Het biedt ROSGard aan, een biologisch kandidaat-geneesmiddel dat nierschade voorkomt door de blootgestelde cellen en weefsels te beschermen, te reinigen en te herstellen. Het bedrijf was voorheen bekend als A1M Pharma AB (publ) en veranderde zijn naam in Guard Therapeutics International AB (publ) in oktober 2019.

Guard Therapeutics International AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Guard Therapeutics International zich tot de beurswaarde?
GUARD fundamentele statistieken
Marktkapitalisatie	SEK 302.45m
Inkomsten(TTM)	-SEK 78.82m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-3.8x

Koers/Winstverhouding

Is GUARD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GUARD resultatenrekening (TTM)
Inkomsten	SEK 0
Kosten van inkomsten	SEK 0
Brutowinst	SEK 0
Overige uitgaven	SEK 78.82m
Inkomsten	-SEK 78.82m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-6.41
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde GUARD op de lange termijn?

Bekijk historische prestaties en vergelijking

GUARD Overzicht aandelen

Beloningen

Risicoanalyse

Guard Therapeutics International AB (publ) Concurrenten

OM:MVIR

SEK 324.2m

OM:LIPUM

SEK 311.8m

OM:ALZ

SEK 324.6m

NGM:CURAS

DKK 236.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Guard Therapeutics Announces First Patient in Europe Dosed in the Clinical Phase 2b POINTER Study

Guard Therapeutics International AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 7.185811 million.

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

Recent updates

Guard Therapeutics Announces First Patient in Europe Dosed in the Clinical Phase 2b POINTER Study

Guard Therapeutics International AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 7.185811 million.

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Revenue and earnings growth

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

No longer forecast to breakeven

New major risk - Share price stability

New major risk - Financial position

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 (Akita) and Advances Clinical Development Program

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

New minor risk - Financial position

New major risk - Revenue and earnings growth

Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA

Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation

Price target decreased by 36% to kr1.61

No longer forecast to breakeven

Price target decreased by 36% to kr1.61

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

No longer forecast to breakeven

Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA

Guard Therapeutics International AB (Publ) Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial

No longer forecast to breakeven

Guard Therapeutics International AB (publ) Receives FDA Fast Track Designation for RMC-035

Guard Therapeutics International AB (publ) Receives IND Approval from the FDA for RMC-035

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Receives Approval from the Swedish Medical Products Agency to Conduct A Clinical Study of RMC-035 in Kidney Transplantation

Price target decreased to kr2.15

High number of new and inexperienced directors

Guard Therapeutics International AB (publ) Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022

Guard Therapeutics International AB (publ) Provides In-Depth Information on Phase 2 Clinical Trial

Guard Therapeutics Announces First Patient Has Been Dosed in Guard Therapeutics' Phase 2 Clinical Trial of ROSgard

Forecast to breakeven in 2024

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Chief Executive Officer recently bought kr1.6m worth of stock

Guard Therapeutics Receives Approval to Expand the Global Phase 2 Study of Rosgard to Canada

Guard Therapeutics’ Application to Conduct a Phase 2 Clinical Trial of ROSgard is Approved by the German Medicines Regulator

Chief Executive Officer recently bought kr300k worth of stock

Guard Therapeutics International AB (Publ) Reports Positive Results from Preclinical Studies

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations

New 90-day high: kr1.50

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Guard Therapeutics International AB (Publ) Completes Pre-IND meeting with FDA

Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021

New 90-day low: kr1.22

New 90-day low: kr1.23

Guard Therapeutics Reports Positive Top-Line Results from Phase 1 Study of Rosgard in Individuals with Renal Impairment

New 90-day high - kr1.60

Rendement voor aandeelhouders

Prijsvolatiliteit